Visual Analogue Scale has higher assay sensitivity than WOMAC pain in detecting between-group differences in treatment effects: A meta-epidemiological study.

Da Costa, B. R.; Saadat, P.; Basciani, R. M.; Agarwal, A.; Johnston, B. C.; Jüni, P. (2021). Visual Analogue Scale has higher assay sensitivity than WOMAC pain in detecting between-group differences in treatment effects: A meta-epidemiological study. Osteoarthritis and cartilage, 29(3), pp. 304-312. Elsevier 10.1016/j.joca.2020.10.004

Text daCosta_OsteoarthritisCartilage_2021.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) | Request a copy

OBJECTIVE

To compare assay sensitivity of the Visual Analogue Scale (VAS) for global osteoarthritis pain and the Western Ontario and McMaster University (WOMAC) pain subscale, and the associated between-trial heterogeneity in effect sizes (ES).

DESIGN

We included trials with placebo, sham or non-intervention control that included at least 100 patients with hip or knee osteoarthritis per arm, reporting both VAS and WOMAC pain scores. ES were calculated as between-group difference in means divided by the pooled standard deviation and compared using a paired t-test. ES and τ2 as a measure of between-trial heterogeneity were combined using random-effects meta-regression with robust variance estimation to account for the correlation of data within trials and meta-analyses.

RESULTS

Twenty-eight trials with 44 randomized comparisons were included. In 28 comparisons (64%), ES from VAS favoured the intervention more than those from WOMAC pain (P=0.003). Twenty-six p-values (59%) were smaller according to VAS (P=0.008). The 44 comparisons contributed to 12 meta-analyses. Eleven meta-analyses (92%) showed larger benefits of interventions according to VAS, with a combined overall difference in ES of -0.08 (95% CI -0.14 to -0.02). τ2 was similar for VAS and WOMAC pain (difference in τ2, -0.003, 95% CI -0.009 to 0.004).

CONCLUSION

The VAS for global pain had slightly higher assay sensitivity at trial and meta-analysis levels than the WOMAC pain subscale without relevant increase in between-trial heterogeneity.

Interest & Impact

Downloads

2 since deposited on 10 Dec 2020
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item